Printer Friendly

BIOJECT FILES REGISTRATION STATEMENT FOR PUBLIC EQUITY OFFERING

 PORTLAND, Ore., Sept. 17 /PRNewswire/ -- Bioject Medical Technologies Inc. (NASDAQ: BJCT) today announced the filing with the Securities and Exchange Commission of a registration statement for the public offering of 2,610,000 shares of Bioject's common stock.
 Bioject is offering 2,509,344 shares and selling shareholders are offering 100,656 shares. The underwriter has the option to purchase an additional 391,500 shares from the company to cover any over-allotments. After consummation of the offering, 12,656,854 shares of common stock will be outstanding. The offering will be underwritten by Pacific Growth Equities and is expected to commence in late October 1993.
 A registration statement relating to these common shares has been filed with the Securities and Exchange Commission but has not yet become effective. These common shares may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Prospectuses may be obtained from Pacific Growth Equities, 353 Sacramento, 16th floor, San Francisco, CA 94111, Attention: Syndicate Department.
 Bioject is an Oregon corporation that develops, manufactures and markets a jet injection system for needle-free drug delivery. Using this technology for injections virtually eliminates the associated risk of contaminated needlestick injuries and related bloodborne pathogen transmission, a major concern throughout the healthcare industry. Additionally, the company is developing a self-injection system for insulin delivery pursuant to an agreement with Eli Lilly and Co., and is seeking relationships with pharmaceutical companies to develop a prefilled configuration of the company's single-use disposable syringe.
 -0- 9/17/93
 /CONTACT: Dan Zenka, APR, or Tim Justice of Bioject, 503-639-7221/
 (BJCT)


CO: Bioject Medical Technologies Inc. ST: Oregon IN: MTC SU: OFR

JH-IC -- SE001 -- 2940 09/17/93 07:48 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1993
Words:340
Previous Article:ROLLINS ENVIRONMENTAL SERVICES REPORTS FOURTH QUARTER EARNINGS ESTIMATE
Next Article:IMMUNEX APPOINTS STEVEN GILLIS ACTING CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters